

Ryan Evans, Elizabeth Gillon-Zhang, Julia Brown, Katherine Knudsen, Candace King, Amanda Green, Ana-Luisa Silva, Justyna Mordaka, Rebecca Palmer, Alessandro Tomassini, Alejandra Collazos, Christina Xyrafaki, Iyelola Turner, Chau Ha Ho, Dilyara Nugent, Jinsy Jose, Simonetta Andreazza, Kristine von Bargen, Eleanor Gray, Magdalena Stolarek-Januszkiewicz, Aishling Cooke, Honey Reddi, Barnaby Balmforth, Robert Osborne

#### ABSTRACT

**Introduction:** Patients can only access the full potential of targeted drugs if they have biomarker testing. Current methods such as NGS are costly and challenging to interpret, while PCR assays are limited in the number of variants they can cover. We developed ASPYRE<sup>®</sup> (Allele-Specific PYrophosphorolysis REaction) technology to address the urgent need for rapid, accessible and affordable diagnostics informing actionable genomic target variants of a given cancer. The targeted ASPYRE-Lung® panel for NSCLC covers 114 variants in 11 genes (ALK, BRAF, EGFR, ERBB2, KRAS, RET, ROS1, MET & NTRK1/2/3) to robustly inform clinical management, based on practice guidelines. The assay detects single nucleotide variants, insertions, deletions, and gene fusions from tissue-derived DNA and RNA simultaneously.

**Methods:** We tested the limit of detection, specificity, analytical accuracy and analytical precision of ASPYRE-Lung using FFPE lung tissue samples from patients with NSCLC, variant-negative FFPE tissue, and FFPE-based contrived samples with controllable variant allele fractions.

**Results:** The sensitivity (LoD95) of ASPYRE-Lung in FFPE lung tissue samples was determined to be  $\leq$  3% variant allele fraction for single nucleotide variants and insertions or deletions,  $\leq$  100 copies for fusions, and  $\leq$  200 copies for MET exon 14 skipping. The specificity was 100% with no false positive results. The analytical accuracy test yielded no discordant variants between ASPYRE-Lung and orthogonal testing (targeted capture NGS) or contrived samples, and results were replicable across operators, reagent lots, runs, and real-time PCR instruments with a high degree of precision. The technology is simple and fast, with a turnaround time of 2 days from sample receipt to result, with analysis via a cloud-based analysis algorithm and no further interpretation or bioinformatic analysis required.

**Conclusion:** ASPYRE-Lung has the potential to be transformative in providing rapid, actionable molecular profiling of tissue for patients with NSCLC.

#### **ASPYRE-Lung ASSAY WORKFLOW**

DNA IVIIVI RNA JVIIVI	TARGET AMPLIFICATION	ENZYMATIC CLEANUP REACTION	ASPYRE REACTION	DETECTION REACTION	DATA ANALYSIS
Instrument requirements	Thermal cycler	Thermal cycler	Thermal cycler	Real-time PCR instrument	Desktop computer
Hands-on Time	30 mins	10 mins	35 mins	15 mins	20 mins
Incubation Time	1 hour 25 mins	15 mins	35 mins	3 hours 30 mins	-

The steps of the ASPYRE-Lung assay workflow after nucleic acid extraction. The TAT from sample receipt to results out is completed at the Biofidelity Genomics Laboratory within 2 days.

#### **STUDY MATERIALS & METHODS**

**Contrived reference samples** Variant-specific DNA (SNVs, indels) and RNA (gene fusions, MET exon 14 skipping) oligonucleotides were manufactured by commercial suppliers, quantified by dPCR, and spiked into background DNA or RNA extracted from blank FFPE tissue samples.

**Clinical samples** FFPE patient tissue blocks were obtained from commercial biobanks.

**Ethical approval** Institutional Review Board (IRB) or equivalent was obtained for sample use in diagnostics development by biobanks through collection sites. All data were de-identified so no patients could be identified by study personnel outside of the clinical trial site including the biobanks and the study authors.

**Nucleic acid extraction** Nucleic acid from 12 µM curls was extracted using the Quick-DNA/RNATM FFPE miniprep kit (Zymo Research). Concentrations were determined by Qubit.

**ASPYRE-Lung** 20 ng DNA and 6 ng RNA were analyzed at the Biofidelity Genomics Laboratory, a CLIA site, using standardized protocols.

**Orthogonal testing** DNA was sequenced through targeted capture and sequencing (Roche Avenio Targeted Assay, Illumina NextSeq 500)

**Interfering substances** Low variant-containing contrived samples were spiked with molecular biology-grade ethanol or guanidinium thiocyanate at concentrations mimicking potential carryover during the extraction process, before testing with ASPYRE-Lung.

**Data analysis** Data from real-time PCR instruments were downloaded and analyzed using custom cloud-based ASPYRELab v1.0.0 software. All variant calling was blinded to results from orthogonal analyses.

## ASPYRE-Lung: Validation of a Simple, Fast, Robust and Novel Method for Multi-Variant Genomic **Analysis of Actionable NSCLC Variants in FFPE Tissue**

### **Biofidelity Inc.\*, Morrisville, United States of America Biofidelity Ltd.\*, Cambridge, United Kingdom**

#### INTRODUCTION TO ASPYRE

Comprehensive genomic testing of EGFR, BRAF, ALK, RET, ROS1, ERBB2, KRAS, NTRK1, NTRK2, NTRK3 and MET is indicated in patients with NSCLC. The detection of abnormalities in these genes informs the use of targeted therapeutic agents. We have previously described development of a novel method, ASPYRE, for rapid and low-cost detection of single nucleotide variants, insertions, deletions and complex events from DNA<sup>1</sup> and fusions and exon skipping from RNA<sup>2</sup>. Here, we describe analytical validation of this assay including testing of sensitivity (LoD95), specificity, analytical accuracy, analytical precision and resiliency to potential interfering substances.

EGFR	BRAF	KRAS	ERBB2
Exon 18 G719A G719S G719C Exon 19 Deletions	Exon 15 V600E	Exon 2 G12A G12V G12C G13A G12D G13C G12F G13D G12R G13R	Exon 17 V659E Exon 20 Insertions
Insertions Exon 20 T790M S768I C797S Insertions		G12S Exon 3 Q61E Q61L Q61H Q61R Q61K	
Exon 21 L858R L861Q			
ALK Fusions Fusions	Fusions Exo	ет n 14 ping	<b>NTRK2</b> Fusions Fusions

Genes and variants covered by the ASPYRE NSCLC tissue panel. A total of 114 genomic variants are assessed and aggregated as actionable variant calls where appropriate for treatment guidance e.g. *NTRK*-fusion positive call is aggregated from multiple potential fusion pairs.

ofidelity.							
,	ASPYRE-Lung Rep	port	ASPYRE				
PATIENT INFORMATION	SPECIMEN DETAILS	ORDERING PHY	SICIAN				
ME: Rosie Cotton	SPECIMEN TYPE: FFPE Tissue	NAME: Thomas Bombadil					
о <b>г віятн:</b> 05 Feb 1960 Unknown	COLLECTION DATE: 01 Aug 2023 RECEIVED DATE: 28 Aug 2023	INSTITUTION: Burrows Onco	logy				
	REPORT DATE: 03 Nov 2023	1					
	ACCESSION ID: BCL23243420 BLOCK ID: B-23-1234	~					
	TEST RESULTS SUMMARY	2					
esult summary comments	TEST RESULTS SUMMART	K					
	CLINICAL INFORMATION AND INDICATION I	FOR TESTING					
C - Non-Small Cell Lung Cancer							
	BIOMARKERS IDENTIF	FIED					
ARKER	VARIANT TYPE	ASSOCIATED THERAPEUTICS*					
F exon 15 p.V600E	Missense	Dabrafenib + trametinib Dabrafenib Vemurafenib					
2KT/2/3 fusion	Fusion	Entrectinib Larotrectinib					
ext indicates NCCN preferred therapeutic			]				
patient tested negative for targeted	BIOMARKERS NOT DETECTED genomic variants in the following genes: ALA						
+	INDETERMINATE BIOMARKERS	5					
results were not conclusive for the f	ollowing targeted genomic variants: EGFR ex	xon 18 p.G7195, RET fusion					
V	RESULT INTERPRETATION						
se, is frequently mutated in NSCLC; <i>i</i> se domain (IPR000719). <i>BRAF</i> is alte <u>v.mycancergenome.org</u> ). Dabrafenib	ically significant missense variant (p.V600E) BRAF V600 is the most common activating n ered in 5.15% of NSCLC patients with BRAF V in combination with trametinib has evidence ncbi.nlm.nih.gov/28919011/; https://pubmed.r	mutation and a mutational hotspot wit 600E present in 1.37% of all NSCLC pa e of efficacy for the treatment of patie ncbi.nlm.nih.gov/27283860/). Single-a	hin the protein atients ( <u>https://</u> nts with BRAF				
	nce of efficacy in patients with BRAF V600E REQUIRED.	under certain circumstances in NSCL0					
CLC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin lents with NSCLC (NCCN guidelines h h NTRKI/2/3-fusion positive solid tun	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466	is estimated that NTRK1/2/3 fusions o b have evidence of efficacy for the trea	C (NCCN Guidelines ccur in 0.2% of atment of patients				ASP
CLC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines f NTRKI/2/3-fusion positive solid tun delines NSCLC v3.2023). Clinical corr delity Clinical Laboratory McCrimmon Parkway, Suite 230	REQUIRED. ically significant NTRK1/2/3 fusion variant. It NSCLC v3.2023). Entrectinib and larotrectinib nors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED.	is estimated that NTRKI/2/3 fusions o b have evidence of efficacy for the trea 8156, https://pubmed.ncbi.nlm.nih.gov/	C (NCCN Guidelines cour in 0.2% of atment of patients 31838007, NCCN Phone: 919-659-3285 Fax: 919-659-3290		SPYRE-Lung Repo		ASP
LC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines i NTRKI/2/3-fusion positive solid tun delines NSCLC v3.2023). Clinical corr delity Clinical Laboratory dcCrimmon Parkway, Suite 230 sville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466	is estimated that NTRK1/2/3 fusions o b have evidence of efficacy for the tree 6156, https://pubmed.ncbi.nlm.nih.gov/ 6156, https://pub	C (NCCN Guidelines cour in 0.2% of itment of patients (31838007, NCCN Phone: 919-659-3285	P	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960		ASP
LC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines i NTRKI/2/3-fusion positive solid tun delines NSCLC v3.2023). Clinical corr delity Clinical Laboratory dcCrimmon Parkway, Suite 230 sville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of b have evidence of efficacy for the tree 6156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv R: 9203871	C (NCCN Guidelines cour in 0.2% of atment of patients 31838007, NCCN Phone: 919-659-3285 Fax: 919-659-3290 fice@biofidelity.com PAGE 1 OF 2 The ASPYRE-Lung assay of cancer (NCCN Guidelines nsertions and duplication exon 3 (missense variants) exchnical issues (see BION ndividual variants are inde	P DATE O DATE O NSCLC Version 3.2023), Incl s), and exon 21 (missense va ); <i>MET</i> exon 14 skipping; and 1ARKERS NOT EVALUATED, eterminate, they will be iden	ATIENT INFORMATION - BCL2324342	to sex: Unknown tats known to be actionable in no riants), exon 19 (indels), exon 20 variants) and exon 20 (insertion <i>IRK1/2/3</i> , except for any variant cover all actionable variants in ARKERS, if applicable). For vari	n-small cell lung (missense variant s); KRAS exon 2 ar s not evaluated di these genes/exon: ants tested and th
LC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines I NTRKI/2/3-fusion positive solid tun elines NSCLC v3.2023). Clinical corr lelity Clinical Laboratory IncCrimmon Parkway, Suite 230 eville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRK1/2/3 fusions of b have evidence of efficacy for the tree 6156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv R: 9203671	C (NCCN Guidelines cour in 0.2% of timent of patients 31838007, NCCN Phone: 919-659-3285 Fax: 919-659-3290 rice@biofidelity.com PAGE 1 OF 2 The ASPYRE-Lung assay of rechnical issues (see BION ndividual variants are inde specific performance char DNA and RNA are extract. DNA and RNA are extract. DNA and RNA are extract.	P DATE O DATE O DATE O DATE O NSCLC Version 3.2023), ind s), and exon 21 (missense va ); MET exon 14 skipping; and 1ARKERS NOT EVALUATED, eterminate, they will be iden acteristics of the ASPYRE-L ed from formalin-fixed, para ts are amplified from DNA a tion (ASPYRE) (Silva et al., 2	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA varian uding <i>EGFR</i> exon 18 (missense var riants); <i>ERBB2</i> exon 17 (missense to fusions in <i>ALK</i> , <i>ROSI</i> , <i>RET</i> , and <i>NI</i> if applicable). The assay does not tified (see INDETERMINATE BIOM ung assay, please visit: biofidelity.c	sex: Unknown ats known to be actionable in no inants), exon 19 (Indels), exon 20 variants) and exon 20 (Insertion <i>IRK1/2/3</i> , except for any variant cover all actionable variants in ARKERS, if applicable). For vari com/products/aspyre-lung/tech at least 10% tumor cellularity. R tts are detected using Allele-Spi s tested and the specific perform	n-small cell lung (missense variant s); KRAS exon 2 ar s not evaluated du these genes/exon- ants tested and th nical-specification
LC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines I NTRKI/2/3-fusion positive solid tun elines NSCLC v3.2023). Clinical corr lelity Clinical Laboratory IncCrimmon Parkway, Suite 230 eville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of b have evidence of efficacy for the tree 6156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv R: 9203871	C (NCCN Guidelines cour in 0.2% of timent of patients 31838007, NCCN Phone: 919-659-3285 Fax: 919-659-3290 rice@biofidelity.com PAGE 1 OF 2 The ASPYRE-Lung assay of cancer (NCCN Guidelines neertions and duplications accon 3 (missense variants) cechnical issues (see BION ndividual variants are inde specific performance char DNA and RNA are extracts cDNA, and RNA are extracts CDNA	P DATE O DATE O	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA variar uding EGFR exon 18 (missense variants); ERBB2 exon 17 (missense variants); ERBB2 exon 18 (missense variants); ERBB2 exo	sex: Unknown  ats known to be actionable in no initis, exon 19 (indels), exon 20 variants) and exon 20 (insertion <i>TRK1/2/3</i> , except for any variant cover all actionable variants in ARKERS, if applicable). For vari com/products/aspyre-lung/tech at least 10% tumor cellularity. R ts are detected using Allele-Spi s tested and the specific perform specifications.  al benefit based on NCCN Guid generate a new report to incorp.	n-small cell lung (missense varian s); <i>KRAS</i> exon 2 a s not evaluated d these genes/exon ants tested and th nical-specification NA is converted t scific nance characteris elines NSCLC v3.2 prate new clinical
CLC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines in <i>NTRKI/2/3</i> -fusion positive solid tun delines NSCLC v3.2023). Clinical corr delity Clinical Laboratory McCrimmon Parkway, Suite 230 sville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of b have evidence of efficacy for the tree 6156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv R: 9203871	C (NCCN Guidelines Cour in 0.2% of Itement of patients Itement of	P ATE O DATE	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA variar uding EGFR exon 18 (missense variants); ERBB2 exon 17 (missense variants); ERBB2 exon 18 (missense variants); ERBB2 exo	sex: Unknown  se	n-small cell lung (missense variant s); <i>KRAS</i> exon 2 ar s not evaluated du these genes/exon ants tested and th nical-specification NA is converted to acific nance characterist elines NSCLC v3.2 orate new clinical ranked in order of dings of other test degment. A genetik ective. Furthermore fective. The see or suggest that suggested by a he clinical and not rule out the stics determined b test to go through. This laboratory i
CLC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines in <i>NTRKI/2/3</i> -fusion positive solid tun delines NSCLC v3.2023). Clinical corr delity Clinical Laboratory McCrimmon Parkway, Suite 230 sville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of b have evidence of efficacy for the tree 6156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv R: 9203871	C (NCCN Guidelines Cour in 0.2% of Itement of patients Itement of	P ATE O DATE	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA variar uding <i>EGFR</i> exon 18 (missense var- riants); <i>ERBB2</i> exon 17 (missense va- fusions in <i>ALK, ROSI, RET,</i> and <i>NI</i> if applicable). The assay does not tified (see INDETERMINATE BIOM ung assay, please visit: biofidelity of <b>METHODS AND LIMITATIONS</b> fin-embedded (FFPE) tissue with nd cDNA by multiplex PCR. Variar 021; Gray <i>et al.</i> , 2022). For variants //products/aspyre-lung/technical- bisCLAIMER ents that are associated with clinic as generated. Biofidelity will not g or arise after the report date. The lift respecties that may be more clinication tory, current clinical findings, or th ly indicate that an associated, listed d on this report does not necessar for use with a particular patient, a sup particular condition. The select nent of the treating physician, takk is based solely upon the results of J he assay. This test was developed US Food and Drug Administratior	sex: Unknown  se	n-small cell lung (missense variant s); <i>KRAS</i> exon 2 at s not evaluated at these genes/exom- ants tested and th nical-specification NA is converted to acific nance characterist elines NSCLC v3.2 orate new clinical ranked in order of dings of other test degment. A genetic ective. The see or suggest that suggested by a he clinical and not rule out the stics determined by test to go through. This laboratory i
CLC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin lents with NSCLC (NCCN guidelines h n NTRKI/2/3-fusion positive solid tun delines NSCLC v3.2023). Clinical corr delity Clinical Laboratory McCrimmon Parkway, Suite 230 isville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of b have evidence of efficacy for the tree \$156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv IR: 9203871	C (NCCN Guidelines Cour in 0.2% of Itement of patients Itement of	P ATE O DATE	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA varian uding EGFR exon 18 (missense variants); ERBB2 exon 17 (missense variants); ERBB2 exon 18 (missense variants); ERBB2 exo	sex: Unknown  se	n-small cell lung (missense variant s); <i>KRAS</i> exon 2 ar s not evaluated du these genes/exon ants tested and th nical-specification NA is converted to acific nance characterist elines NSCLC v3.2 orate new clinical ranked in order of dings of other test degment. A genetik ective. Furthermore fective. The see or suggest that suggested by a he clinical and not rule out the stics determined b test to go through. This laboratory i
LC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines i NTRKI/2/3-fusion positive solid tun delines NSCLC v3.2023). Clinical corr delity Clinical Laboratory dcCrimmon Parkway, Suite 230 sville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of b have evidence of efficacy for the tree \$156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv IR: 9203871	C (NCCN Guidelines cour in 0.2% of atment of patients 31838007, NCCN Phone: 919-659-3285 Fax: 919-659-3290 rice@biofidelity.com PAGE 1 OF 2 The ASPYRE-Lung assay of cancer (NCCN Guidelines neertions and duplication axon 3 (missense variants), rechnical issues (see BIOM ndividual variants are indo specific performance char DNA and RNA are extracts DNA and RNA are extrac	P ATE O DATE	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA varian uding EGFR exon 18 (missense variants); ERBB2 exon 17 (missense variants); ERBB2 exon 18 (missense variants); ERBB2 exo	sex: Unknown  se	n-small cell lung (missense variant s); <i>KRAS</i> exon 2 ar s not evaluated du these genes/exon ants tested and th nical-specification NA is converted to acific nance characterist elines NSCLC v3.2 orate new clinical ranked in order of dings of other test degment. A genetik ective. Furthermore fective. The see or suggest that suggested by a he clinical and not rule out the stics determined b test to go through. This laboratory i
LC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin ents with NSCLC (NCCN guidelines in NTRKI/2/3-fusion positive solid tun lelines NSCLC v3.2023). Clinical corr delity Clinical Laboratory AcCrimmon Parkway, Suite 230 sville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of b have evidence of efficacy for the tree \$156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv IR: 9203871	C (NCCN Guidelines Cour in 0.2% of Itement of patients Sala380007, NCCN  Phone: 919-659-3285 Fax: 919-659-3290 Itemerity Phone: 919-659-3290 Itemerity Itemerity Phone: 919-659-3290 Itemerity Itemerity Phone: 919-659-3285 Fax: 919-659-3290 Itemerity Itemer	P avaluates NCCN guideline-re NSCLC Version 3.2023), Ind s), and exon 21 (missense va b); MET exon 14 skipping; and tARKERS NOT EVALUATED, eterminate, they will be iden acteristics of the ASPYRE-L ed from formalin-fixed, para ts are amplified from DNA a ion (ASPYRE) (Silva et al., 2 y, please visit: biofidelity.com nation about therapeutic ag- rate at the date the report w rker interpretations that may cacy, and do not include the e or based on the clinical his red here does not necessani coption may not be suitable fective for the treatment of a he sole discretion and judgm nent decisions should not be w the limits of detection of f cleared or approved by the is test is used for clinical pur- t Laboratory Improvement A 21. Single-copy detection of s 22. Ultra-sensitive molecular	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA variar uding <i>EGFR</i> exon 18 (missense var- riants); <i>ERBB2</i> exon 17 (missense va- fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fin-embedded (FFPE) tissue with nd cDNA by multiplex PCR. Variar 021; Gray <i>et al.</i> , 2022). For variants //products/aspyre-lung/technical- //products/aspyre-lung/technical- tory, current clinical findings, or th by indicate that an associated with clinic as generated. Biofidelity will not 6; arise after the report date. The lift rapeuties that may be more clinicat for use with a particular patient, a inty particular condition. The select then of the treating physician, takk is based solely upon the results of 1 he assay. This test was developed US Food and Drug Administration poses. It should not be regarded a mendments (CLIA) as qualified to LAB DIRECTOR SIGNATURE Biomatic variants from solid and ling detection of gene fusions from RM CN) clinical practice guidelines in of a starting provide a guidelines in of BIORECTOR SIGNATURE	sex: Unknown  sex: Unknown  sex: Unknown  ts known to be actionable in no inants), exon 19 (indels), exon 20 inants, exore a lactionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For vari com/products/aspyre-lung/tech  at least 10% tumor cellularity. R is are detected using Allele-Spi is tested and the specific perform specifications.  at least 10% tumor cellularity of the rapeutic agents are not ally appropriate based on NCCN Guid generate a new report to incorp sted therapeutic agents are not ally appropriate based on the fir he treating physician's clinical ju id therapeutic option will be eff rily indicate that it will not be ef ind the report does not guarant it tion of any potential treatment : as investigational or for research is a investigational or for research is perform high complexity clinical perform high complexity clinical uid biopsy. <i>Scl Rep.</i> 11(1):6068. NA using ASPYRE. <i>BMC Med Gen</i>	n-small cell lung (missense variants); KRAS exon 2 ais s not evaluated di these genes/exon ants tested and th nical-specification NA is converted to soffic nance characteris elines NSCLC v3.2 prate new clinical ranked in order of idings of other test dgment. A geneti ective. Furthermo fective. The se or suggested by a he clinical and not rule out the stics determined to test to go throug . This laboratory testion al laboratory testion in test of the stics determined to test to go throug . This laboratory testion al laboratory testion in the stics determined to test to go throug test to go throug . This laboratory testion al laboratory testion and rule out the stics determined to test to go throug . This laboratory testion al laboratory testion al laboratory testion and the stics determined to the stics determined to test to go through the stics determined to test to go through the stics determined to test to go through the stics determined to the stics determined to test to go through the stics determined to the stics determined to test to go through the stics determined to the stics determined to test to go through the stics determined to the stics determined to test to go through the stics determined to the s
CLC v3.2023 ). Clinical correlation is F ASPYRE-Lung assay detected a clin lents with NSCLC (NCCN guidelines h h NTRKI/2/3-fusion positive solid tun delines NSCLC v3.2023). Clinical corr delity Clinical Laboratory McCrimmon Parkway, Suite 230 isville, NC 27560	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of b have evidence of efficacy for the tree \$156, https://pubmed.ncbi.nlm.nih.gov/ email: customerserv IR: 9203871	C (NCCN Guidelines Cour in 0.2% of Itement of patients Sala380007, NCCN  Phone: 919-659-3285 Fax: 919-659-3290 Itemerity Phone: 919-659-3290 Itemerity Itemerity Phone: 919-659-3290 Itemerity Itemerity Phone: 919-659-3285 Fax: 919-659-3290 Itemerity Itemer	P avaluates NCCN guideline-re NSCLC Version 3.2023), ind s), and exon 21 (missense va ); MET exon 14 skipping; and IARKERS NOT EVALUATED, eterminate, they will be iden acteristics of the ASPYRE-L ed from formalin-fixed, para ts are amplified from DNA a tion (ASPYRE) (Silva <i>et al.</i> , 2 y, please visit: biofidelity.com nation about therapeutic ag- rate at the date the report w rker interpretations that may cacy, and do not include the e or based on the clinical his- ret dere does not necessari option may not be suitable fective for the treatment of a he sole discretion and judgm nent decisions should not be w the limits of detection of 1 cleared or approved by the is test is used for clinical pur I Laboratory Improvement A 21. Single-copy detection of st 22. Ultra-sensitive molecular ensive Cancer Network (NCC	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA variar uding <i>EGFR</i> exon 18 (missense var- riants); <i>ERBB2</i> exon 17 (missense va- fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fin-embedded (FFPE) tissue with nd cDNA by multiplex PCR. Variar 021; Gray <i>et al.</i> , 2022). For variants //products/aspyre-lung/technical- //products/aspyre-lung/technical- tory, current clinical findings, or th by indicate that an associated with clinic as generated. Biofidelity will not 6; arise after the report date. The lift rapeuties that may be more clinicat for use with a particular patient, a inty particular condition. The select then of the treating physician, takk is based solely upon the results of 1 he assay. This test was developed US Food and Drug Administration poses. It should not be regarded a mendments (CLIA) as qualified to LAB DIRECTOR SIGNATURE Biomatic variants from solid and ling detection of gene fusions from RM CN) clinical practice guidelines in of a starting provide a guidelines in of BIORECTOR SIGNATURE	sex: Unknown  sex: Unknown  sex: Unknown  ts known to be actionable in no inants), exon 19 (indels), exon 20 inants, exore a lactionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For vari com/products/aspyre-lung/tech  at least 10% tumor cellularity. R is are detected using Allele-Spi is tested and the specific perform specifications.  at least 10% tumor cellularity of the rapeutic agents are not ally appropriate based on NCCN Guid generate a new report to incorp sted therapeutic agents are not ally appropriate based on the fir he treating physician's clinical ju id therapeutic option will be eff rily indicate that it will not be ef ind the report does not guarant it tion of any potential treatment : as investigational or for research is a investigational or for research is perform high complexity clinical perform high complexity clinical uid biopsy. <i>Scl Rep.</i> 11(1):6068. NA using ASPYRE. <i>BMC Med Gen</i>	n-small cell lung (missense variant s); KRAS exon 2 ar s not evaluated du these genes/exons ants tested and th nical-specification NA is converted to scific nance characterist elines NSCLC v3.2 prate new clinical ranked in order of idings of other tes dgment. A genetic ective. Furthermore fective. The se or suggested by a he clinical and not rule out the stics determined by test to go throug . This laboratory i estimation al laboratory testimation is laboratory testimation in the stics determined by test to go through . This laboratory is and al laboratory testimation commits. 15(1):215.
CLC v3.2023 ). Clinical correlation is F e ASPYRE-Lung assay detected a clin tients with NSCLC (NCCN guidelines f	REQUIRED. ically significant NTRK1/2/3 fusion variant. It VSCLC v3.2023). Entrectinib and larotrectinib hors (https://pubmed.ncbi.nlm.nih.gov/29466 elation is REQUIRED. www.biofidelity.com	is estimated that NTRKI/2/3 fusions of bhave evidence of efficacy for the tree 6156, https://pubmed.ncbi.nlm.nih.gov/ remail: customerserv R: 9203871	C (NCCN Guidelines Cour in 0.2% of Itement of patients Sala380007, NCCN  Phone: 919-659-3285 Fax: 919-659-3290 Itemerity Phone: 919-659-3290 Itemerity Itemerity Phone: 919-659-3290 Itemerity Itemerity Phone: 919-659-3285 Fax: 919-659-3290 Itemerity Itemer	P DATE O Evaluates NCCN guideline-re NSCLC Version 3.2023), Ind s), and exon 21 (missense va ); <i>MET</i> exon 14 skipping; and IARKERS NOT EVALUATED, eterminate, they will be iden acteristics of the ASPYRE-L ed from formalin-fixed, para ts are amplified from DNA a tion (ASPYRE) (Silva et al., 2 y, please visit: biofidelity.com nation about therapeutic ag- rate at the date the report w rker interpretations that may cacy, and do not include the e or based on the clinical hus ted here does not necessari option may not be suitable fective for the treatment of a he sole discretion and judgm nent decisions should not be w the limits of detection of 1 cleared or approved by the is test is used for clinical pur- lis test is used for clinical pur- test test test test test test test test	ATIENT INFORMATION - BCL2324342 F BIRTH: 05 Feb 1960 BIOMARKERS EVALUATED commended DNA and RNA variar uding <i>EGFR</i> exon 18 (missense var- riants); <i>ERBB2</i> exon 17 (missense va- fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fusions in <i>ALK, ROSI, RET</i> , and <i>NI</i> if applicable). The assay does not fin-embedded (FFPE) tissue with nd cDNA by multiplex PCR. Variar 021; Gray <i>et al.</i> , 2022). For variants //products/aspyre-lung/technical- //products/aspyre-lung/technical- tory, current clinical findings, or th by indicate that an associated with clinic as generated. Biofidelity will not 6; arise after the report date. The lift rapeuties that may be more clinicat for use with a particular patient, a inty particular condition. The select then of the treating physician, takk is based solely upon the results of 1 he assay. This test was developed US Food and Drug Administration poses. It should not be regarded a mendments (CLIA) as qualified to LAB DIRECTOR SIGNATURE Biomatic variants from solid and ling detection of gene fusions from RM CN) clinical practice guidelines in of a starting provide a guidelines in of BIORECTOR SIGNATURE	sex: Unknown  sex: Unknown  sex: Unknown  ts known to be actionable in no inants), exon 19 (indels), exon 20 inants, exore a lactionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For variant cover all actionable variants in ARKERS, if applicable). For vari com/products/aspyre-lung/tech  at least 10% tumor cellularity. R is are detected using Allele-Spi is tested and the specific perform specifications.  at least 10% tumor cellularity of the rapeutic agents are not ally appropriate based on NCCN Guid generate a new report to incorp sted therapeutic agents are not ally appropriate based on the fir he treating physician's clinical ju id therapeutic option will be eff rily indicate that it will not be ef ind the report does not guarant it tion of any potential treatment : as investigational or for research is a investigational or for research is perform high complexity clinical perform high complexity clinical uid biopsy. <i>Scl Rep.</i> 11(1):6068. NA using ASPYRE. <i>BMC Med Gen</i>	n-small cell lung (missense variant s); KRAS exon 2 ar s not evaluated du these genes/exons ants tested and th nical-specification NA is converted to scific nance characterist elines NSCLC v3.2 prate new clinical ranked in order of idings of other tes dgment. A genetic ective. Furthermore fective. The se or suggest that suggested by a he clinical and not rule out the stics determined by test to go throug . This laboratory i estin al laboratory testin normics. 15(1):215.

sample details, a summary of test results including biomarkers identified, biomarkers not detected and indeterminate biomarkers, and an interpretation of results.

#### RESULTS

Variant type	Gene	Total positive/ total tests*	
	DNA		
	KRAS exon 2 G12C COSM526		
	EGFR exon 21 L858R COSM6224	00/00	
SNV	EGFR exon 20 T790M COSM6240	80/80	
	BRAF exon 15 V600E COSM476		
Deletion	EGFR exon 19 E746-A750del COSM6223		
	ERBB2 exon 20 Y772-A775dup COSM20959	60/60	
Insertion	EGFR exon 20 A767-V769dup COSM12376		
	RNA Fusions		
	<i>EML4-ALK</i> E13_A20 COSM408		
	<i>KIF5B-RET</i> K15_R12 COSF1232		
	CD74-ROS1 C6_R36 COSF1200		
Fusion	<i>TMP3-NTRK1</i> T8_N10 COSF1329	118/120	
	QKI-NTRK2 Q6_N16 COSF1446		
	ETV6-NTRK3 E5_N15 COSF571		
	RNA Exon Skipping		
Exon skipping	MET	20/20	

**LoD95 confirmation data.** Results of testing 20 replicate contrived samples at levels pre-determined by an LoD estimation (range 3-10% VAF for SNV/InDel, 100-300 copies for gene fusions and 200-800 copies for MET exon 14 skipping). Confirmed LoD95 by mutation class (SNV, indel, fusion and *MET* exon 14 skipping) were ≤ 3% VAF for SNV and indel,  $\leq$  100 copies for fusions, and  $\leq$  200 copies for *MET* exon 14 skipping. \*Results were aggregated across the given variant class. NA, not applicable.

Level	Metric	Actual % (Cl95)	
Comple	PPA	100 (90-100)	
Sample	NPA	100 (91-100)	
Mariant	PPA	100 (92-100)	
Variant	NPA	100 (99.87-100)	

Summary of analytical accuracy of ASPYRE-Lung assessed using contrived and clinical samples. Shown are the PPA and NPA obtained for each sample and for each variant across both clinical contrived sample types, for DNA & RNA combined and the associated 95% confidence intervals.

#### **TP / total Replicates**

		Guanidine thiocyanate				
Analyte	Gene	VAF/ Copies	5 % Ethanol	5 mM	10 mM	20 mM
DNA	KRAS exon 2 G12C COSM516	6%	5/5	5/5	5/5	5/5
DNA	EGFR exon 21 L858R COSM6224	6%	5/5	5/5	5/5	5/5
RNA	EML4- ALK E13_A20 COSF408	200 copies	5/5	5/5	5/5	5/5
RNA	KIF5B- RET K15_R12 COSM1232	200 copies	5/5	5/5	5/5	5/5

Contaminants carried over from FFPE sample extraction do not interfere with the ASPYRE-Lung assay. Two DNA and two RNA contrived samples at twice the LoD95 were spiked with ethanol or guanidinium thiocyanate to mimic carryover from substances used during sample extraction. Shown are the positive calls made compared to total runs from the subsequent ASPYRE-Lung assay runs. NA, not applicable.

#### DISCUSSION

Our data from this sample set demonstrates that ASPYRE-Lung is highly sensitive and specific with performance characteristics appropriate for use in a clinical laboratory. We believe that ASPYREbased testing can provide more rapid and efficient genomic evaluation of individuals with NSCLC as the full ASPYRE-Lung assay (from sample receipt to reporting) is routinely completed in our CLIA laboratory within 2 days. This provides rapid genomic evaluation relative to current workflows.

Many NGS panel-based tests are available, yet patient access to critical biomarker testing remains poor (<50% of patients in the US<sup>3</sup>) and gaps remain due to the cost, complexity and long turnaround times associated with NGS. In contrast, ASPYRE-Lung testing processes are simple and fast with only four reagent transfer steps after DNA/RNA extraction that require no more than pipetting and standard lab equipment. ASPYRE results are also simpler to interpret and much more readily adapted for display in an electronic medical record in discrete data fields than a multi-page NGS report. Given its breadth of coverage and technical performance characteristics we believe that ASPYRE can address numerous gaps in current NSCLC biomarker testing practices.

# Biofidelity.

			Nun	nber	
Category	Nucleic acid	Samples	Neg variant calls / sample	Positive	Total negative calls
	DNA	105	65	0	6825
LoD estimation	RNA	95	4	0	380
	DNA	140	65	0	9100
LoD confirmation	RNA	140	4	0	560
	DNA	24	66	0	1584
Analytical Precision	RNA	24	5	0	120
	DNA	7	65	0	455
Analytical Accuracy (single mutant)	RNA	7	4	0	28
Analytical Accuracy (double mutant)	DNA	3	64	0	192
	DNA	60	66	0	3960
LoB	RNA	60	5	0	300
Total					23504

Negative variant calls from samples tested during AV. A single 'Reportable Variant' may cover multiple nucleotide variants where the associated therapeutics are identical: ASPYRE-Lung tests for 114 variants, and outputs 71 potential calls. The negative calls from all experiments performed during assay validation were combined to estimate a **false positive** rate of 0% (Cl95 0-0.0157%)

Sample-level metric	Actual % (Cl95)
PPA	100 (86-100)
NPA	100 (93-100)

Summary of analytical precision (repeatability and reproducibility) data. Shown are the positive and negative percent agreement values between runs of ASPYRE-Lung, aggregated over DNA and RNA, demonstrating 100% reproducibility (inter-run precision) and repeatability (intra-run precision). Samples were assayed in four independent runs across four days by two operators using two real-time PCR instruments and two reagent

#### SUMMARY

#### ASPYRE<sup>®</sup>

- is a novel technology based on pyrophosphorolysis of oligonucleotide probes perfectly hybridized to sample-derived target DNA or cDNA (RNA) sequences.
- combines the benefits of multi-gene testing with rapid TAT
- has simple bioinformatics, and with easily interpretable clinical decision making (only actionable markers are tested)

In this study, we demonstrate that ASPYRE-Lung FFPE Tissue assay has excellent analytical sensitivity, comparable to current NGS-based testing solutions:

- $\leq$  3% VAF for SNV and indels from DNA
- ≤ 100 copies for gene fusions from RNA
- $\leq$  200 copies *MET* exon 14 skipping from RNA.

The assay has **100% specificity** with no false positive results out of 23,504 negative calls made from all samples run.

The assay is also highly reproducible and repeatable across different operators, reagent lots, runs, days and qPCR instruments.

**No interfering effects** from carry over of extraction reagents were detected.

#### REFERENCES

1. Silva et al. 2021. Single-copy detection of somatic variants from solid and liquid biopsy. *Sci Rep.* 11(1):6068. 2. Gray et al. 2022. Ultra-sensitive molecular detection of gene fusions from RNA using

ASPYRE. BMC Med Genomics. 15(1):215.

3. Sadik et al. 2022. Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer. JCO Precision Oncology 6:e2200246

Data from this study have been prepared and submitted for publication. \*All authors are employees of Biofidelity Inc pf Biofidelity Ltd and may have a financial interest including salary, equity, options, and intellectual property.